Maria Gavriatopoulou researcher
Gavriatopoulou, Maria
VIAF ID: 7634156497235717740006 (Personal)
Permalink: http://viaf.org/viaf/7634156497235717740006
Preferred Forms
- 100 1 _ ‡a Gavriatopoulou, Maria
- 100 0 _ ‡a Maria Gavriatopoulou ‡c researcher
4xx's: Alternate Name Forms (1)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity | |
Cholangiocarcinoma: investigations into pathway-targeted therapies | |
Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia | |
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction | |
Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis | |
Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases | |
The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group | |
Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with mu | |
COVID-19: time to flatten the infodemic curve | |
Current Approaches in the Management of Hepatic Adenomas | |
The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia | |
Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance | |
Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma | |
Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies | |
Disappearing liver metastases: A systematic review of the current evidence | |
Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma. | |
Efficacy and safety of elotuzumab for the treatment of multiple myeloma | |
Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis | |
Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM | |
Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease | |
Emerging treatment approaches for myeloma-related bone disease | |
Emerging treatment strategies for COVID-19 infection | |
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias | |
Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma | |
Expression of CCL3 by Neoplastic Cells in Patients with Waldenström's Macroglobulinemia: An Immunohistochemical Study in Bone Marrow Biopsies of 67 Patients | |
Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy | |
Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis. | |
High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients | |
Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications | |
Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience | |
Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. | |
Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period | |
Management of multiple myeloma bone disease: impact of treatment on renal function | |
Meat, fish, dairy products and risk of hematological malignancies in adults - a systematic review and meta-analysis of prospective studies | |
Mechanisms of bone destruction in multiple myeloma. | |
Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools | |
Multiple myeloma: Role of autologous transplantation | |
Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma. | |
Next generation flow cytometry for MRD detection in patients with AL amyloidosis | |
Organ-specific manifestations of COVID-19 infection | |
Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection | |
Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia | |
Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis | |
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). | |
Prognostication of the High-Risk WM Patient | |
Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia | |
Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial | |
Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis | |
Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group | |
Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause | |
The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma | |
Screening for Gaucher disease among patients with plasma cell dyscrasias | |
Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. | |
Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy | |
Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis | |
TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma. | |
Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop | |
Treatment of Bing-Neel syndrome with first line sequential chemoimmunotherapy: A case report | |
Treatment of light chain deposition disease with bortezomib and dexamethasone | |
Updates on thrombotic events associated with multiple myeloma | |
Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH) | |
VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT. | |
Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients |